IMMUNE CORRELATES OF RESPONSE TO IMMUNE CHECKPOINT BLOCKADE IN ACUTE MYELOID LEUKAEMIA

Immunological classifiers that predict patient outcome and therapeutic responses have been constructed through targeted immune gene expression profiling of pre-treatment bone marrow samples from patients with acute myeloid leukaemia treated with pembrolizumab and hypomethylating agent azacytidine (clinicaltrials.gov identifier: NCT02845297). In the study presented here, a well annotated cohort of adults with relapsed/refractory acute myeloid leukaemia was used to acquire immune gene expression data. An immune exhaustion and senescence-related gene set was shown to correlate with poor response to immune checkpoint blockade.